In addition, cancer dependence on EZH2 sometimes relies on genetic alterations of the SWI/SNF chromatin remodeling complex, making EZH2 an epigenetic target for drugs based on synthetic lethality (65, 66). The gene discussed is EZH2; the disease is cancer.